Xeris Biopharma Holdings, Inc. (XERS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.53-0.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Achieve and sustain positive net income: EPS -0.18 vs >0 target.
Xeris raised 2026 revenue guidance to about $385 million. Sales grew 38% from 2025-Q1 to 2026-Q1. Net income turned positive at $2.2 million in 2026-Q1. The company is fixing losses and growing steadily.
Litigation and capital deals may hurt finances. Profit gains could stall. Growth might slow below analyst hopes.
The price is about 54% above our fair value near $5.7. Analysts expect 32% revenue growth. We see risk if growth or profits weaken.
Breaks if: Fail to execute or reverse exchange agreements in 2026-Q2
Reduce debt by exchanging $23 million principal of 2028 Convertible Notes for cash and stock to improve balance sheet and reduce interest expense.
Stated in 2 disclosures in 2026-Q2. The company eliminated approximately $23 million of 8.00% Convertible Senior Notes debt through exchange agreements involving cash and stock, resulting in expected annual interest savings of about $2 million. This capital allocation action aligns with management's stated focus on improving the balance sheet and reducing interest expense.
“Entered into privately negotiated exchange agreements eliminating approximately $23 million of debt via cash and stock issuance.”
“Currently, no 2028 Convertible Notes remain outstanding following exchanges and conversions in July 2026.”
Breaks if: Net income falls below zero over next 4 quarters
Breaks if: Revenue falls below $380 million in FY26
Drive revenue growth primarily through Recorlev's commercial momentum and tighten full-year 2026 revenue guidance to $385-$390 million.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $60.1 million in 2026-Q1 to $92.1 million in 2026-Q2, driven by 34% net product revenue growth year-over-year primarily from Recorlev. Management has progressively tightened 2026 full-year revenue guidance from $375-$390 million to $385-$390 million, reflecting delivery and confidence in growth trajectory.
“We are tightening our full-year guidance to $385 million to $390 million, reflecting confidence in the team, portfolio, and trajectory.”
“We remain confident in our ability to deliver on our full-year financial targets and raised the bottom end of our 2026 revenue guidance to $380 million to $390 million.”
“We expect total revenue to range from approximately $375 million to $390 million for 2026.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
XERS represents a speculative growth investment with a focus on improving profitability and revenue. The current thesis state is intact, despite recent mixed signals and a muted price reaction.
The market appears to be pricing in a durable premium compared to peers, reflecting expectations for continued growth. However, the valuation is considered unjustified given the company's loss-making status and recent earnings miss.
Fundamentals show potential for improvement, as management is focused on increasing revenue guidance and maintaining positive net income. Recent financial performance has been strong, but risks remain due to the high-miss-rate nature of the industry.
The thesis hinges on management's ability to deliver on revenue guidance and navigate potential sector challenges. Key factors include the performance of sector bellwethers and overall economic conditions that could impact investor sentiment.
In the next 1-3 years, XERS will need to demonstrate consistent execution to justify its current valuation amidst elevated risks. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company increased its revenue guidance for 2026. It also advanced XP-8121 into Phase 3 clinical development. However, the latest earnings report showed a miss, which raises concerns.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.